Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)

N. Cohn, Jay; A. Pfeffer, Marc; L. Rouleau, Jean; Sharpe, Norman; Swedberg, Karl; Straub, Matthias; G. Wiltse, Curtis; J. Wright, Theressa; the MOXCON Investigators, for

doi:10.1016/s1388-9842(03)00163-6

Public

Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)

Published in European Journal of Heart Failure • Oct 1, 2003

Authors:

Jay N. Cohn

Marc A. Pfeffer

Jean L. Rouleau

Abstract

BACKGROUND: The association between sympathetic activation and mortality in chronic heart failure and the favorable effect of beta blocking drugs has raised the possibility of therapeutic efficacy for central sympathetic inhibition with sustained-release (SR) moxonidine, an imidazoline receptor agon...

Subject

Moxonidine

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!